Clinical Trials Logo

Filter by:
NCT ID: NCT05070702 Completed - Healthy Clinical Trials

First in Human Study of CT-1500 in Healthy Participants

Start date: November 8, 2021
Phase: Phase 1
Study type: Interventional

This study is a single center, randomized, placebo-controlled, double-blind study of CT-1500 in healthy volunteers. The study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses and multiple ascending doses of orally administered CT-1500 compared to placebo.

NCT ID: NCT05065970 Completed - Clinical trials for Immunoglobulin A (IgA) Nephropathy

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

IGNAZ
Start date: August 31, 2021
Phase: Phase 2
Study type: Interventional

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

NCT ID: NCT05056441 Completed - Crohn Disease Clinical Trials

A Study of Real-World Outcomes of People With Crohn's Disease (CD)

EVOLVE
Start date: December 1, 2021
Phase:
Study type: Observational

The main aim of this study is to compare long-term remission in participants receiving vedolizumab (VDZ) and those receiving ustekinumab (UST). In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to visit a study doctor during this study.

NCT ID: NCT05054530 Completed - Clinical trials for Overweight and Obesity

Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106

Start date: November 11, 2021
Phase: Phase 1
Study type: Interventional

This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106 in healthy, overweight or obese subjects.

NCT ID: NCT05053334 Completed - Healthy Volunteers Clinical Trials

Biosimilar Study Comparing PK, PD, Safety and Immunogencity of BP11 With US Licensed Xolair and EU Approved Xolair

Start date: February 16, 2022
Phase: Phase 1
Study type: Interventional

A single dose, double blind comparative trial to assess the pharmacokinetics, pharmacodynamics, safety and immunogenicity of 3 different products (BP11, US-Xolair and EU-Xolair) containing 150mg of Omalizumab as subcutaneous injection in healthy male volunteers.

NCT ID: NCT05053165 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

Start date: January 4, 2022
Phase: Phase 1
Study type: Interventional

The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.

NCT ID: NCT05046665 Completed - Clinical trials for Urothelial Carcinoma

Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients

ZiPUP
Start date: May 14, 2021
Phase: Phase 1
Study type: Interventional

The aim of this study is to determine if it is practical to use 89Zr-TLX250 PET/CT in the staging and detection of localized and metastatic urothelial carcinoma or bladder cancer. The primary objective is to evaluate the feasibility of using 89Zr-TLX250 PET/CTas a new diagnostic and staging modality to detect urothelial carcinoma or bladder cancer.

NCT ID: NCT05046522 Completed - Migraine Clinical Trials

A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Migraines.

Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

This is a double-blind randomised controlled study to evaluate the effectiveness of orally-dosed Palmitoylethanolamide (PEA) compared to placebo for reducing pain severity and duration of migraines in otherwise healthy participants aged 18 years and older.

NCT ID: NCT05045807 Completed - Clinical trials for Health Risk Behaviors

Nitrate INFORMER Nitrosamine Study

Start date: October 11, 2021
Phase: N/A
Study type: Interventional

Nitrate is a controversial component of vegetables, meat, and drinking water. The now well-established benefits of nitrate, through the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway, on cardiovascular risk factors and long-term cardiovascular disease risk are tarnished by a continuing concern about a link between nitrate ingestion and cancer. This can result in misguided advice to avoid consumption of high-nitrate leafy green vegetables by both the media and the scientific literature. A recent media headline stated, "Cancer alert over rocket: trendy salad leaves exceed safe levels of carcinogenic nitrates in one in every ten samples". One scientific review stated, "the presence of nitrate in vegetables, as in water and generally in other foods, is a serious threat to man's health". Controversy in the literature, and gaps in the knowledge are leading to confusing messages around vegetables that may play a critical role in cardiovascular health. The major dietary sources of nitrate are vegetables, meat, and drinking water. Source of nitrate could be a crucial factor determining whether the consumption of nitrate is linked with beneficial (such as improving cardiovascular health) versus harmful (N-nitrosamine formation) effects. For example, unlike meat and water-derived nitrate, vegetables contain high levels of vitamin C and/or polyphenols that may inhibit the production of N-nitrosamines. So far, no study has investigated the formation of N-nitrosamines after consumption of these different sources in humans. A pilot study will be conducted to determine that endogenous N-nitrosamine formation is observed after ingestion of meat with added nitrate and nitrite and that consumption of vegetables with the meat containing added nitrate and nitrite will inhibit the production of N-nitrosamines.

NCT ID: NCT05043623 Completed - COVID-19 Clinical Trials

Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior

Start date: August 26, 2021
Phase: N/A
Study type: Interventional

A study to investigate Rhinoswab as an alternative method to combined throat and deep nasal (CTDN) swab for respiratory sample collection in children who present to the Royal Children's Hospital (RCH) for viral testing. Children and their parent/guardian will answer a short survey about their preferences. Laboratory staff will answer a short survey about handling the different samples.